Peripheral T-cell lymphoma treatment - late-stage difficult-to-treat challenges remain, the efficacy of new drugs can be expected.

!---- 2020 POST-ASCO Conference Information Exchange will be held.the meeting online and offline combination, the various kinds of big curry gathered together, opened a full of work academic feast.Professor Li Wenyu of Guangdong Provincial People's Hospital explained the current incidence, treatment strategies and research and development of new drugs in the external week t-cell lymphoma.clinical challenges remain, the need to meet the needs of T-cell lymphoma in non-Hodgkin's lymphoma (NHL) is not high, Europe and the United States accounted for about 10%, China's data is about 21%, in our hospital (Guangdong Provincial People's Hospital) about 28%, the incidence is relatively low., the subtype with the most incidence of T-cell lymphoma in Europe and the United States is peripheral T-cell lymphoma (PTCL), about 20%.due to the large number of T-cell lymphoma sympoids, the number of each subtype is relatively small, resulting in the current understanding of the disease, research and research and research of new drugs relatively small.in general, PTCL to lymph nodes swelling or organ violation mainly, patients often accompanied by fever, and the overall treatment effect is not good. After first-line treatmentpatients, the 5-year survival rate is only about 30%.the long-term survival of the other subtypes is extremely low, except for the ALK-positive ALCL subtype.most patients who have first-line treatment will relapse within 1 year, and after the application of conventional chemotherapy, their survival is often less than half a year.therefore, PTCL has the characteristics of complex performance, difficult to treat routine, short survival of patients, its clinical cure needs are far from being met, but also a major challenge in the clinical treatment of lymphoma.early treatment is good, and late stages are difficult as early as 20 years ago, PTCL used B-cell lymphoma chop program for treatment.the cure rate of B-cell lymphoma is about 50%, and the single division of T-cell lymphoma shows that long-term survival is only 20% to 30%.but in the progress reported at this year's EHA and ASCO meetings, a retrospective study analyzed 250 patients treated with CHOP programs, and the results suggested that 52 percent of patients with phase I to II had 52 percent progression less progression (PFS) and 58 percent total 5-year survival (OS)., the efficacy of using CHOP in early young patients is relatively good., however, the proportion of advanced patients in the whole PTCL patient population reached 75% to 80%, the efficacy is not good, is still a clinical problem to be solved.new drug offers hope, the beneficiary still needs to expand in the field of PTCL new drug research and development, breakthrough siphons are mainly two types.class is histone deacetylase (HDAC) inhibitors, this new drug has been listed at home and abroad, its overall efficiency of about 20%, OS can reach more than 1 year, for some patients with relapse difficult to cure brought a new breakthrough.but overall, the proportion of patients with effective HDAC treatment is small, and which patients are beneficiaries are still being explored.another type of CD30 mono-anti-SGN-35, from structural analysis, SGN-35 is not a simple antibody, but also coupled with microtube inhibitor drugs.CD30 monotoresist treatment of PTCL patients is more efficient, but it is mainly aimed at CD30-positive patients, so the application has certain limitations.in short, all kinds of new drugs have brought new hope to the treatment of PTCL patients, but at the same time there are their own limitations.Treatment of PTCL is still difficult and needs to be explored.Li Wenyu, director physician, master's tutor, M.D., Director of The Oncology Center of Guangdong Provincial People's Hospital - Lymphoma Department - Executive Director, Chairman of the Professional Committee of The Association of Women Physicians of Guangdong Province, Deputy Chairman of the Oncology Branch of Guangdong Medical Association, Deputy Chairman of the Medical Association of Guangzhou, Deputy Chairman of the Professional Committee of The Guangzhou Society of Cancer Lymphoma, Member of the American Blood Association, caca Youth Committee.Amiee Source: Tumor Information, !-- Content Presentation Ends - !-- Determine Signed-down